TEANECK, N.J.--(BUSINESS WIRE)--Virbac and Phibro Animal Health have entered into an agreement under which Phibro will represent and market Virbac’s newly approved TULISSIN® 100 brand of tulathromycin (DIN # 02502879). Virbac has received approval from Health Canada for TULISSIN 100, which is indicated for use in cattle, swine and sheep.
TULISSIN 100 is a strong fit to support Canadian cattle and swine producer herd health protocols, as well as a strong addition to Phibro’s portfolio of ruminant and swine products including V-Max®, Neo-Terramycin®, Terramycin®, Stafac® and PRO-Banminth®. TULISSIN 100 will be marketed and supported by Phibro’s experienced team.
Phibro is excited to market this product and extend its portfolio, offering this trusted tool to Canadian cattle, swine and sheep producers to help them treat disease and reduce death loss associated with respiratory disease. This tool will help Canadian producers provide a healthy and affordable supply of food for consumers in Canada and abroad.
TULISSIN 100 will be available beginning in January 2021 from your veterinarian. For more information, please contact your local Phibro representative.
Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for livestock, helping veterinarians and farmers produce healthy, affordable food while using fewer natural resources. For more information, visit pahc.com.
Virbac - Focusing on Animal Health, From the Beginning
Virbac offers veterinarians, farmers and pet owners in more than 100 countries a practical range of products and services to diagnose, prevent and treat the majority of pathologies, while improving the animals’ quality of life. With these innovative solutions covering more than 50 species, Virbac contributes, day after day, to shape the future of animal health.